Peptide medicine has grown faster than the systems meant to keep it honest. GLP-1 drugs taught millions of Americans that peptides are real medicine, demand spilled into a much wider category of compounds, and an economy of clinics, pharmacies, and online sellers grew up around it. What never grew up alongside it was the plumbing that mature fields of medicine take for granted. There is still no reliable way to know who is qualified to prescribe these compounds, what is actually in the vial being dispensed, or whether anyone is learning anything from the patients already being treated.
Karthik Achari spent years inside that world before he started measuring it. A clinician by training and a Doctor of Nursing Practice candidate at Bradley University, he built and operated businesses in pharmaceutical and peptide manufacturing and distribution, and later in precision diagnostics. That work put him inside supply chains most patients never see, and it left him with a conviction that runs through everything he has built since: quality is a series of decisions someone makes, not a property a product has. He has since divested those interests and holds no operating role in them.
In January 2026, Achari founded PepMD, an independent standards body developing the credentialing and trust infrastructure for peptide medicine. It is the first organization he is aware of to bring clinician credentialing, pharmacy recognition, and research site authorization together under a single standard. PepMD does not credential, recognize, or authorize his former businesses.
“Being authorized to prescribe a peptide and being qualified to prescribe one are two different things, and nothing in the current system tells you which is which,” Achari says. “A license means the state says you may practice. It says nothing about whether you’ve had a single hour of training on the compound you’re about to inject into someone. Most of medicine fills that gap with layers above the license. Peptide medicine has none of them yet.”
From inside the supply chain
Achari is careful not to describe the problem as fraud, and his account of how the field actually fails is more uncomfortable than a story about bad actors would be.
“Legal and trustworthy aren’t the same thing,” he says. “Every fast-growing industry goes through a stretch where that gap is wide open and nobody’s checking it. I watched it from the inside. Nobody in the chain was lying. And nobody was checking the question that actually matters.”
In July 2026, Achari delivered public comment during the Open Public Hearing of the FDA’s Pharmacy Compounding Advisory Committee, which voted to recommend several peptides for reconsideration under the compounding pathway. The vote was advisory, rulemaking is still ahead, and the committee takes up additional peptides in early 2027. Achari declines to cheer regulatory outcomes in either direction, a restraint that has made him a frequent voice in national coverage of the field rather than an advocate within it.
“My position is safe access and harm reduction. The exposure already exists, and pushing it underground helps nobody. But harm reduction has a floor, and the floor is that somebody stands behind the product.”
Three questions, three functions
PepMD’s model maps onto the three questions the field can’t currently answer. Nothing above a state license indicates whether a prescriber has any peptide-specific training, so clinical credentialing verifies that providers are qualified in peptide medicine specifically. Paperwork alone can’t establish what is actually in a compounded vial, so pharmacy recognition holds compounding pharmacies to a peptide-specific quality standard, supported by independent product testing through an accredited laboratory network. And because almost nothing captures what happens to patients afterward, research site authorization brings IRB-governed structure to real-world practice, turning outcomes into documented evidence rather than anecdote.
The organization’s design is deliberately austere. PepMD does not sell peptide education, does not sell products, and does not hold ownership stakes in the businesses it evaluates. Its fees pay for verification work, never for a favorable outcome. Recognized entities appear in its registry on equal terms, and directory placement is not sold. Achari describes that structure as the entire point: verification only means something when the outcome isn’t for sale.
The evidence problem is the one he talks about with the most urgency. A national news investigation this year surveyed all 50 states and found that adverse events from peptide use are, in most of the country, not systematically tracked at all. Achari was quoted in that reporting, as he has been in Newsweek and Fox News Digital coverage of the field this year.
“Nobody can tell you whether harm is rare or just unrecorded,” he says. “The evidence isn’t absent. It’s fragmented. Millions of people are using compounds with no completed trials behind them, and almost none of that experience is captured in a form anyone can learn from. That’s not a chemistry problem. It’s an infrastructure problem.”
The road ahead
The written PepMD Standard is in final form, and the founding cohort of credentialed clinicians, recognized pharmacies, and authorized research sites is being assembled. Achari’s measure of success borrows from fields that made the same transition before this one: hospitals before accreditation, imaging before quality standards, compounding itself a generation ago. None of them stopped being controversial because the argument was won. They stopped being controversial when the checking arrived.
“In ten years I’d like peptide medicine to be boring, in the best possible way.”
PepMD exists, as Achari puts it, so that anyone treating or being treated with peptides can tell the difference between what is legal and what is trustworthy.
